Estrogen Receptor Beta 2 antibody | 57/3

100% Secure


Mouse anti Human Estrogen Receptor Beta 2

Product Type
Monoclonal Antibody
Clone
57/3
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
MCA2279 P* 0.1 mg
MCA2279GT P* 50 µg
Mouse anti Human Estrogen Receptor beta 2 antibody, clone 57/3 recognizes the estrogen receptor beta 2 isoform, expressed in cell nuclei of a range of human tissues including the ovary, placenta, testis and vas deferens. No cross-reactivity is seen with estrogen receptor beta 1 isoform.

The detection of estrogen (ER) and progesterone (PR) receptors using immunohistochemical staining of formal fixed paraffin embedded (FFPE) tissue, has gradually replaced ligand binding assays (LBA), to become the most common method for the determination of the ER/PR status of breast tumors. Approximately 75% to 80% of breast tumors have estrogen and/or progesterone receptors, and the presence of these receptors helps determine both the patient’s prognosis and the effectiveness of hormonal therapy

Product Details

Target Species
Human
Product Form
Purified IgG - liquid
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09% Sodium Azide (NaN3)
Immunogen
Synthetic peptide derived from the C terminus of the human estrogen receptor beta 2 isomer, CGMKMETLLPEATMEQ.
Approx. Protein Concentrations
IgG concentration 1.0mg/ml
Fusion Partners
Spleen cells from immunized Balb/c mice were fused with cells of the SP2/0 myeloma cell line.

Storage Information

Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
18 months from date of despatch.

More Information

UniProt
Q92731 Related reagents
Entrez Gene
ESR2 Related reagents
Regulatory
For research purposes only

Applications of Estrogen Receptor Beta 2 antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Immunohistology - Paraffin 1 1/50 1/500
Western Blotting
  1. 1This product requires antigen retrieval using heat treatment prior to staining of paraffin sections.Sodium citrate buffer pH 6.0 is recommended for this purpose. Glycine/ EDTA preparations have also been used with success in some tissues
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using the appropriate negative/positive controls.
Histology Positive Control Tissue
Testis

Application Based External Images

Immunohistology - Paraffin

Product Specific References

References for Estrogen Receptor Beta 2 antibody

  1. Saunders, P.T. et al. (2002) ERbeta1 and the ERbeta2 splice variant (ERbetacx/beta2) are expressed in distinct cell populations in the adult human testis.
    J Clin Endocrinol Metab. 87 (6): 2706-15.
  2. Critchley, H.O. et al. (2002) Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle.
    J Clin Endocrinol Metab. 87 (11): 5265-73.
  3. Gaskell, T.L. et al. (2003) Differential expression of two estrogen receptor beta isoforms in the human fetal testis during the second trimester of pregnancy.
    J Clin Endocrinol Metab. 88 (1): 424-32.
  4. Scobie, G.A. et al. (2002) Human oestrogen receptors: differential expression of ER alpha and beta and the identification of ER beta variants.
    Steroids. 67 (12): 985-92.
  5. Wong, N.A. et al. (2005) ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates.
    J Pathol. 207 (1): 53-60.
  6. Collins, F. et al. (2009) Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha.
    BMC Cancer. 9: 330.
  7. Carpino, A. et al. (2007) Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor.
    Eur J Endocrinol. 157 (2): 239-44.
  8. Miller, W.R. et al. (2006) Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment.
    Br J Cancer. 94 (9): 1333-8.
  9. Rago, V. et al. (2009) Identification of ERbeta1 and ERbeta2 in human seminoma, in embryonal carcinoma and in their adjacent intratubular germ cell neoplasia.
    Reprod Biol Endocrinol. 7: 56.
  10. Skliris, G.P. et al. (2006) Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours.
    Br J Cancer. 95 (5): 616-26.
  11. Critchley, H.O. et al. (2002) Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle.
    J Clin Endocrinol Metab. 87 (11): 5265-73.
  12. Ciucci, A. et al. (2014) Gender effect in experimental models of human medulloblastoma: does the estrogen receptor β signaling play a role?
    PLoS One. 9 (7): e101623.
  13. Ciucci, A. et al. (2015) Mitochondrial estrogen receptor β2 drives antiapoptotic pathways in advanced serous ovarian cancer.
    Hum Pathol. 46 (8): 1138-46.
  14. Zannoni, G.F. et al. (2016) Sexual dimorphism in medulloblastoma features.
    Histopathology. 68 (4): 541-8.
  15. Buttarelli, M. et al. (2017) Hormone receptor expression profile of low-grade serous ovarian cancers.
    Gynecol Oncol. Feb 20. pii: S0090-8258(17)30150-6. [Epub ahead of print]
  16. Ciucci, A. et al. (2018) Estrogen receptor β: Potential target for therapy in adult granulosa cell tumors?
    Gynecol Oncol. 150 (1): 158-65.